Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Iconix Biosciences

Premium
Affymetrix and Iconix Biosciences this week announced the launch of the ToxFX Analysis Suite, a toxicogenomics tool that the firms claim will improve researchers' understanding of safety issues associated with new drug candidates, compounds, or environmental toxicants.
 
According to Affy and Iconix, ToxFX combines Iconix' automated analysis with Affymetrix' GeneChip arrays to generate safety profiles that can diagnose or predict more than 50 toxicological outcomes. It also examines the gene expression changes in 22 biological pathways, offering understanding of the underlying mechanisms of toxicity.
 
Researchers can perform the analysis by generating gene expression data from rat samples on either the GeneChip Rat ToxFX 1.0 Array or the Rat Genome 230 2.0 Array. The data are then compared to the Iconix Drug Signatures and pathway response libraries and cross-referenced to identify matches to known toxicological responses. A toxicity profile report is then generated for the compound based on this information.
 
The tool is available from Affymetrix.
 
Affymetrix also recently launched its GeneChip Cotton Genome Array, a single chip comprised of 23,977 probe sets representing 21,854 cotton transcripts.
 
According to Affy, the Cotton Genome Array is based on EST sequences obtained from four species of Cotton: Gossypium hirsutum, G. raimondii, G. arboretum, and G. barbadense.
 
The company has also released its GeneChip Chromosome 21/22 2.0R Array, a second-generation chip for studying human chromosomes 21 and 22.
 

The single chip contains over 2.3 million probe pairs to interrogate chromosomes 21 and 22 for transcript mapping or chromatin immunoprecipitation experiments.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.